This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: Envision Healthcare Goes Public

NEW YORK ( TheStreet) -- Clayton Dubilier & Rice-backed Envision Healthcare Holdings (EVHC - Get Report) priced its upsized initial public offering at $23 per share, at the top of the expected $20 to $23 range, raising $966 million on Tuesday.

The Greenwood Village Colo.-based provider of outsourced medical and ambulance services sold 42 million shares; it had originally planned to offer 35 million shares. Private equity backer CD&R did not sell any shares in the IPO. At the IPO price, its stake of 128.9 million shares is valued at $2.96 billion.

That, added to the $428 million dividend Envision paid CD&R in October, brings the private equity firm's realized and unrealized gain to about 3.8 times the $887.1 million in equity it paid for the company in 2011, based on financial information in the company's filings.

CD&R acquired the company, then known as Emergency Medical Services Corp., in February 2011 in a deal valued at $3.2 billion. The acquisition was done via its Clayton, Dubilier & Rice Fund VIII, which closed in 2009 with $5 billion.

Envision's shares opened at $25.25 on its first day of trading; they traded up to a high of $25.69 by the afternoon.

The company said it will use proceeds of the IPO to redeem the outstanding $450 million principal amount of its PIK notes at about 102.75% of the principal amount plus accrued and unpaid interest, which it estimated to be around $17.2 million.

Envision posted adjusted EBITDA of $105.9 million on revenue of $899.3 million in the second quarter of 2013, up from adjusted EBITDA of $96.3 million on revenue of $801.1 million in the same quarter of the previous year.

Envision Healthcare listed on the New York Stock Exchange under the ticker symbol "EVHC." Goldman Sachs &, Barclays, Bank of America Merrill Lynch and Citigroup acted as the lead bookrunners on the deal.

-- Written by Taina Rosa in New York

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
EVHC $37.01 0.00%
AAPL $129.96 0.00%
FB $80.44 0.00%
GOOG $539.18 0.00%
TSLA $248.35 0.00%

Markets

DOW 18,011.94 -28.43 -0.16%
S&P 500 2,109.60 -2.13 -0.10%
NASDAQ 5,076.5240 -6.4050 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs